The noted HIV researcher reflects on recent advances, the search for a cure, and the long road ahead.
Bictegravir, an emerging integrase inhibitor that is co-formulated with two other anti-HIV drugs, showed an efficacy similar to Tivicay (dolutegravir) in a phase III clinical trial.
Sanjabi talks about her early interest in science, her innovative research toward an HIV cure, and the importance of mentoring early career investigators.
Researchers estimated a total body burden of as many as seven million cells expressing HIV RNA at any given time in tissues, despite viral load suppression to undetectable levels in the blood.
Two oral presentations and numerous posters at the 16th European AIDS Conference included new data on using dolutegravir-based dual ART (many with 3TC) as a switch option for people currently on stable three-drug ART.
Signal That ABX464 Reduces Viral Reservoir but Not Time to Viral Rebound After Treatment Interruption
New data presented at EACS 2017 suggested that the investigational REV inhibitor ABX464 might reduce the HIV viral reservoir in a study that included a treatment interruption.
Other Names: 744 LA, CAB, GSK-1265744, GSK1265744, GSK744, GSK744 LA, GSK744 LAP, S-265744, S/GSK1265744, cabotegravir LA, cabotegravir sodium Drug Class: Integrase Inhibitors Molecular Formula: C19 H17 F2 N3 O5 Registry Number: 1051375-10-0 (CAS) Ch...
Highlights of major findings on new antiretroviral therapies, including data on long-acting injectable solutions and new combination treatments packed into a single pill.
Effects of the Anti-Inflammatory Antibody Canakinumab on Heart Disease and Cancer: Implications for HIV?
New study results prompt the question of whether canakinumab or other anti-inflammatories could have salutary clinical effects in HIV-positive people.
Many approaches being pursued as cancer therapeutics are also being studied in the context of HIV cure research, including immune checkpoint inhibitors, cytokine therapies, genetically modified chimeric antigen receptor (CAR) T cells and other gene t...